Form 4: Adicet Bio Director's Stock Option Repricing Rescinded, Options Reverted to Original Terms

Director Steve Dubin's stock options in Adicet Bio were repriced back to their original exercise prices following a board decision to rescind a previous repricing.

Summary

• On August 21, 2024, Adicet Bio's Board of Directors approved the rescission of the August 2023 stock option repricing for certain non-employee directors.
• As a result, Steve Dubin's affected stock options have been reverted to their original exercise prices as established at the time of the grant.
• The reported transactions involve stock options with varying exercise prices and expiration dates.
• The shares subject to these options are fully vested and exercisable as of August 21, 2024.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a change in stock option terms. The sentiment is slightly positive as it suggests the company is actively managing director compensation.

Positives

• The rescission of the repricing and reversion to original terms could be seen as a move towards fairer compensation for non-employee directors.
• The fact that the shares are fully vested and exercisable provides immediate potential value to the director.

Industry Context

Changes in director compensation, particularly regarding stock options, are common and closely monitored in the biotech industry. Repricing and subsequent rescission can reflect adjustments to align incentives with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry, used to align their interests with those of shareholders.
• Repricing of stock options is less common but can occur when a company's stock price has significantly declined, potentially to maintain the incentive value of the options.
• The decision to rescind a repricing is relatively unusual and may indicate a change in the company's compensation philosophy or a response to shareholder feedback.

Stakeholder Impact

• Shareholders may view the rescission of the repricing as a positive step towards aligning director compensation with company performance.
• The director, Steve Dubin, is directly impacted by the change in stock option terms.

Key Dates